

## Cumulative Index 1989

### Volume 5

- 
- February** GERIATRIC DERMATOLOGY, pages 1-257  
**May** SLEEP DISORDERS IN THE ELDERLY, pages 259-424  
**August** NEW DEVELOPMENTS IN NEUROPSYCHOLOGICAL EVALUATION, pages 425-638  
**November** HYPERTENSION, pages 639-858
- 

*Note:* Page numbers for complete issues and articles appear in boldface type.

- Abdomen, examination of, in hypertension, 728  
Abdominal fat, and hypertension, 659  
Acetylcholine synthesis, decreased, in Alzheimer's disease, 434  
Acne rosacea, 200-201  
Acral lentiginous melanoma, 175  
Acrochordons, 190-191  
Actinic elastosis, 223, 236  
histopathology of, 134-135  
Actinic keratoses, 229-230  
clinical features of, 163-164  
histology of, 164  
malignant progression of, 162-166  
treatment of, 165-166  
Action, hierarchical organization of, 500-503  
Activities of daily living scales, for independent living skills assessment, 472  
of quality of life, 708  
Adiposity, and hypertension, 658-659  
Adrenal hyperplasia, hyperaldosteronism vs, 759  
Adrenergic inhibitors, adverse effects of, 693  
central, cost of, 832-833  
for hypertension, 808-809  
effect on concomitant disease, 700  
in renal disease, 821-822  
Adrenergic receptors, imbalance of, in isolated systolic hypertension, 667  
Affect, assessment of, 441-459  
AGE products, formation of, in aging, 12  
Age(ing), amino acid racemization in, 11-12  
and impotence, 301-314  
association with blood pressure, 640-644  
biologic, molecular basis of, 1-21  
changes in sleep with, 275-287  
cutaneous carcinogenesis in, 161-162  
dysdifferentiation theory of, 13-14  
effect on epidermal immune function, 149-160  
fibroblast model of, 23-25  
importance of appearance in, 213-214  
in-vitro studies of, 23-40  
in-vivo correlations with, 27  
lymphokines in, 151-158  
nonenzymatic glycosylation in, 12-13  
normal, cognitive decline in, 532-533

- Alcohol (*Continued*)  
     effect on sleep-related respiratory disturbance, 401
- Alcohol restriction, for hypertension, 770
- Alopecia, androgenetic, 205-207
- Alpha-blockers, adverse effects of, 693  
     cost of, 832-833  
     for hypertension, effect on concomitant disease, 699  
     in renal disease, 822
- Alzheimer's disease, and indifference to disability, 447  
     assessment of, 536. See also *Alzheimer's Disease Assessment Scale*.  
     neuropsychological, pathologic validity of, 428-431  
     behavioral markers in, 436  
     biochemistry of, 434-438  
     biomarkers of, search for, 296  
     cognitive decline in, measurement of, 531  
     daytime sleep in, 295  
     dementia in, 533-534  
     depression in, 445  
     disturbed sleep in, neural basis for, 290  
     Huntington's disease vs, 602  
     Wechsler Memory Scale-Revised for, 611-632  
     intrusion errors in, 624-627  
     location of lesions in, 436  
     memory disorders in, 572  
     mental status examinations in, 555  
     neuropathological changes in, 425-440  
     neuropsychological changes in, 425-440  
     neurotransmitters in, 434-438  
     nighttime awakening in, 294  
     nonsomatic treatment of, 427  
     personality profile in, 456-457  
     REM sleep in, 292-293  
     scoring systems for, 291  
     sleep in, 289-299  
         changes in, 263  
         patterns of, 290-294  
         stages of, 293  
     sleep/wake patterns in, 289-299, 295
- Alzheimer's Disease Assessment Scale*, correlation with disease duration, 556  
     for cognitive function assessment, 555  
     for mood assessment, 453-454
- Amadori product, formation of, in aging, 12
- Amino acid racemization, in aging, 11-12
- Aminoguanidine, anti-aging effects of, 13
- Amnesia, bitemporal, 570-571  
     defective insight with, 482  
     dementia vs, on Wechsler Memory Scale-Revised, 614
- diencephalic, 569-570
- drug-induced, 397
- global, transient, 571
- post-traumatic, 508
- psychogenic, 572
- types of, 569-572
- Amyloid deposits, in Alzheimer's disease, 430-433
- Angina pectoris, antihypertensive agents in, 814  
     metoprolol for, 815  
     with snoring, 350
- Angioplasty, for renovascular hypertension, 764-765
- Angiotensin-converting enzyme inhibitors, adverse effects of, 693  
     cost effectiveness of, 837-839  
     cost of, 833-834  
     for hypertension, 807-808  
         effect on concomitant disease, 699  
     in congestive heart failure, 817  
     in coronary artery disease, 816  
     in diabetes mellitus, 820  
     in renal disease, 822  
     quality of life with, 709-712
- Anguish, with brain lesions, 442
- Angular cheilitis, 199-200
- Animals, age-related sleep changes in, 363-369  
     relations to human aging, 367-368  
     physiologic function in, relationship to sleep, 368-369
- Anomia, as memory disorder, 568
- Anosognosia, in brain injury, 483  
     in dementia, 480
- Antidepressants, for depression-associated sleep disturbances, 268-269
- Antihistamines, and drug-induced sleepiness, 398
- Antihypertensive agents, adverse effects of, 691-702  
     quality of life with, 696-697  
     reduction of, 701  
     ambulatory monitoring of, 745  
     and drug-induced sleepiness, 398  
     choice of, 803-811  
     classes of, 804-809  
     clinical trials of, 692-696  
     cost effectiveness of, 834-835  
     cost of, 832-834  
     disease aggravation by, 697-698  
     effect on concomitant disease, 699-700, 813-828  
     functional impairment with, 697-698  
     in chronic obstructive pulmonary disease, 818  
         in congestive heart failure, 817-818  
         in depression, 823-824  
         in diabetes mellitus, 818-820  
         in left ventricular hypertrophy, 816-817  
         in renal disease, 820-823  
         in stroke, 823  
         limitations of, 698  
         long-term use of, safety in, 700  
         physician evaluation of, 705  
         quality of life with, 703-715

- side effects of, 692-700
- Antioxidants, exogenous, in cellular protection against oxidative free radical damage, 9-11
- Anxiety, and performance speed, 510
- Aortic coarctation, and hypertension, 754
- Aortic insufficiency, blood pressure measurement in, 723
- Aortic rigidity, increased, in hypertension, 663
- Apathy, with frontal lobe damage, 503
- Apnea, central, definition of, 315  
in sleep loss recovery, 412  
mixed, definition of, 315  
obstructive, airflow pressures and, 320  
definition of, 315  
sleep. See *Sleep apnea*.
- Apnea index, 350  
and mortality, 356
- Appearance, psychology of, in elderly, 213-222
- Appetite, assessment of, in dietary hypertension therapy, 778
- Arousal threshold, in sleep loss recovery, 412
- Arrhythmias, with sleep apnea, 322, 350
- Arterial stiffness, and pseudohypertension, 725-726
- Angiography, in renovascular hypertension, 762
- Ascorbate, in cellular protection against oxidative free radical damage, 10
- Asteatosis, 196-197
- Asthma, antihypertensive agents in, 818
- Atenolol, cost of, 833  
for hypertension, COOPE study of, 687-689  
in renal disease, 821  
quality of life with, 711  
side effects in, 696
- Atherogenesis, acceleration of, with hypertension, 663
- Atherosclerosis, antihypertensive agents in, 814  
blood pressure measurement in, 723
- Atrial natriuretic peptides, in congestive heart failure, 817-818
- Attention, assessment of, 614-621  
decreased in dementia, 492  
memory vs. on Wechsler Memory Scale-Revised, 613  
role in memory, 567
- ATTMH. See *Australian Therapeutic Trial in Mild Hypertension*.
- Australian Therapeutic Trial in Mild Hypertension, 685-687  
design of, 685-686  
results of, 686-687  
treatment effectiveness in, 831
- Autoantibodies, increase in, age-related, 150
- B cells, and humoral immunity, 150-151
- Baldness, male-pattern, 206
- Baroreceptor reflexes, impaired, 666  
in hypertension, 663
- Barrier properties, of skin, 115-117, 121
- Barthel Index, for independent living skills assessment, 468
- Basal cell carcinoma, 166-167
- Basal lamina, in aging skin, 88
- Beck depression inventory, for mood assessment, 449-450
- Behavioral assessment, in dietary hypertension therapy, 778-779
- Behavioral interventions, for hypertension, 777  
rationale for, 792-794
- Behavioral Problem Checklist, for caregivers, 465
- Behavioral slowing, with aging, 504-506
- Benzodiazepines, and drug-induced sleepiness, 397  
effect on sleep-related respiratory disturbance, 400
- Beta-Blocker Heart Attack Trial, drug side effects in, 695
- Beta-blockers, adverse effects of, 693  
cost of, 833  
for hypertension, 806-807  
effect on concomitant disease, 699  
reduced efficiency of, 663  
in asthma, 818  
in chronic obstructive pulmonary disease, 818  
in coronary artery disease, 814-815  
in depression, 823-824  
in diabetes mellitus, 819  
in renal disease, 821  
quality of life with, 706, 710-711
- Bilirubin, in cellular protection against oxidative free radical damage, 10
- Biologic aging, molecular basis of, 1-21
- Blessed, Tomlinson, Roth Dementia Scale, correlation with Alzheimer's Disease Assessment Scale, 556  
for personality assessment, 451-452
- Blood count, complete, in hypertension, 728
- Blood flow, in skin, age-related changes in, 117-118
- Blood pressure, ambulatory monitoring of, 733-751  
accuracy of, 739-741  
automated, 737-739  
circadian rhythms of, 746  
correlation with office measurements, 739-741, 743  
cost effectiveness of, 747-748  
data analyses of, 741-743  
diagnostic implications of, 743-747  
equipment for, 735-739  
errors in, detection of, 741-742

- Blood pressure (*Continued*)  
 ambulatory monitoring of, practicality of, 735, 747-748  
 prognostic implications of, 745  
 technician training in, 741  
 therapeutic implications of, 745  
 association with age, 640-644  
 classification of, 718  
 factors affecting, 642-646  
 high. See *Hypertension*.  
 intra-arterial, cuff pressure vs, 724-725  
 measurement of, ambulatory. See under *ambulatory monitoring of*.  
 follow-up criteria for, 719  
 home, self-initiated, 735-737  
 indirect, accuracy of, 724-726  
 need for repetition of, 723-724  
 office, correlation with ambulatory monitoring, 743  
 insufficiency of, 734-735  
 technical considerations in, 721-723  
 systolic, association with mortality, 648  
 diastolic vs, as cardiovascular risk predictors, 650  
 variability of, 719-720, 734-735  
 age-related increase in, 724
- Blood pressure manometers, technical considerations in, 721-723
- Blood sugar, fasting, association with blood pressure, 643
- Blood urea nitrogen, measurement of, in hypertension, 728
- Blue nevus, 94
- Brain injury, etiologies of, differentiation by age, 605  
 focal, mania with, 445-446  
 pragnosia following, 448
- Breaking strength, of incisional wounds, 184-185
- Breathing, sleep-disordered, clinical evaluation of, 323-324  
 in depression, 267
- Browning, nonenzymatic, in aging, 12
- Bullous pemphigoid, 193
- Bumetanide, in renal disease, 821
- Burden Interview, for caregivers, 464
- Buttock skin, electron microscopy of, 81-84
- Caffeine, and drug-induced insomnia, 398-399
- Calcium, in hypertension, 661-662, 728
- Calcium antagonists, adverse effects of, 693  
 for hypertension, effect on concomitant disease, 699
- Calcium channel blockers, cost effectiveness of, 837-838  
 cost of, 833-834  
 for hypertension, 807
- in congestive heart failure, 817  
 in coronary artery disease, 816  
 in diabetes mellitus, 820  
 in renal disease, 822-823
- Caloric intake, assessment of, in dietary hypertension therapy, 778
- Cambridge Mental Disorders of the Elderly Examination, in dementia, 536
- Capillary, arterial, vascular wall thickening in, 82  
 venous, normal appearance of, 79
- Captopril, cost of, 833  
 annual, 837  
 for hypertension, 808  
 in renal disease, 822  
 quality of life with, 706, 710-711
- Carbohydrate intake, assessment of, in dietary hypertension therapy, 779
- Carcinogenesis, cutaneous, and aging, 161-162
- Carcinoma, basal cell, 166-167  
 squamous cell, progression of actinic keratoses to, 162-166
- Cardiac system, in hypertension, 658
- Cardiopulmonary dysfunction, in sleep apnea, 321
- Cardiovascular disease, hypertension and, 651  
 mortality from, 640, 650  
 in Hypertension Detection and Follow-up Program, 680-681  
 quality of life with, 704
- Cardiovascular drugs, and drug-induced insomnia, 399
- Caregiver burden, with dementia, assessment of, 464-465
- Catalase, in cellular protection against oxidative free radical damage, 6-7
- Catecholamines, urinary, in hypertension, 757
- Category Test, age-related decrements in, 599-600
- Cations, role in hypertension, 661-662
- Cats, age-related sleep changes in, 366-367
- Cautiousness, increase with aging, 505-506
- Ceiling effects, in cognitive measurement scales, 522-523
- Cell-mediated immunity, age-related changes in, 151
- Cell migration, in wound healing, 186
- Cell proliferation, in wound healing, 185
- Cellular aging, in vivo-in vitro correlations of, 27
- Cellular differentiation, alterations in, with aging, 15
- Cellular senescence, genetic control of, 29-31  
 in nonfibroblast lines, 25-26
- Center for Epidemiological Studies Depression Scale, of quality of life, 708
- Cerebrovascular disease, blood pressure and, 647

- mortality from, 648, 650
- Ceruloplasmin**, in cellular protection against oxidative free radical damage, 10
- Cheilitis**, angular, 199–200
- Cherry hemangioma**, 191
- Chest radiography**, in hypertension, 729
- Chloride**, measurement of, in hypertension, 728
- Chlorthalidone**, for hypertension, 804–805  
in coronary artery disease, 815  
quality of life with, 711
- Choking**, in sleep apnea, 321
- Cholesterol**, in hypertension, 728  
with antihypertensive therapy, 694
- Cholinergic neurotransmitters**, in Alzheimer's disease, 434
- Chondrodermatitis nodularis helicis**, 192
- Choroid**, pigment cells in, 105
- Chronic obstructive pulmonary disease**,  
antihypertensive agents in, 818
- Chymotrypsin**, effect on skin aging, 85
- Circadian rhythm**, 331–346  
amplitude of, age and, 332–333  
free-running, in elderly, 334–339  
sleep during, 340–342  
masking effects in, 332  
phases of, age and, 333  
tolerance to changes in, 342–343  
psychological, 343  
relationship to sleep, in animals, 369–370  
unmasking studies of, in elderly, 333–334
- Circadian system**, 331–332
- Circulatory disease**, death rates from, 639
- Clonidine**, cost of, 833  
for hypertension, 809  
effect on concomitant disease, 700  
in diabetes mellitus, 820  
in renal disease, 822  
quality of life with, 710
- Cognition**. See also under *Cognitive*.  
controlled vs automatic processing in, 537
- Cognitive ability**, fluid vs crystallized, 536–537, 597
- mental status examinations of, correlation of, 557–559
- Cognitive deficits**, assessment of, instruments for, 534–536  
differential diagnosis of, Halstead-Reitan Test Battery for, 601–602  
in Alzheimer's disease, charting of, 537–538  
neurophysiological correlates of, 431–433  
in dementia, measurement of, 519–530
- Cognitive function**, brief measures of, 552  
general screening tests of, 553–555  
interactions with sleep, in animals, 371–375  
neuropsychological assessment of, 441
- Cognitive mental status examinations**, 545–564
- Cognitive scales**, administration of, 528–529  
application of, 529  
difficulty level of, 527–528  
for demented populations, 521–523  
for normal and demented populations, 524–529  
for normal populations, use in dementia, 519–521  
of quality of life, 709  
types of items for, 524–527
- Collagen(s)**, age-related changes in, 60–63, 127–147  
biochemistry of, 128–131  
categories of, 128  
decrease in, with photoaging, 226, 238, 241  
degeneration of, in actinic elastosis, 85  
metabolism and synthesis of, with aging, 135–138  
structure of, 129  
synthesis of, in wound healing, 186  
rate of, age-related changes in, 136
- Colloid milia**, 230–231
- Communication**, assessments of, 470–471
- Comprehension subtest**, for judgment assessment, 490
- Concentration**, assessment of, on Wechsler Memory Scale-Revised, 616  
difficulties in, snoring and, 386  
role in memory, 567
- Confusional states**, memory disorders in, 573
- Contact dermatitis**, 194–195  
prevalence rates for, 47
- Contact sensitivity**, in aging skin, 155–156
- Continuous positive airway pressure**, for sleep apnea, 325
- Contraction**, of open wounds, 183–184
- COOPE study**, description of, 687–689  
design of, 687  
results of, 688–689  
treatment effectiveness in, 831  
treatment schedule for, 687–688
- Cornary artery spasm**, beta-blockers in, 814–815
- Cornell Scale for Depression in Dementia**, 452–453
- Corneocytes**, age-related changes in, 116  
normal turnover of, 121–123
- Coronary artery disease**, antihypertensive agents in, 813–816
- Cosmetics**, psychology of, 218–221
- Cost effectiveness**, definition of, 834
- Counseling group**, in Heartsavers Lifestyle Management Program, 796
- Creatinine**, in hypertension, 728, 759  
with antihypertensive therapy, 694

- Cultural practices, assessment of, in dietary hypertension therapy, 779
- Cushing's disease, and hypertension, 754
- Cushing's syndrome, and hypertension, 759
- Cutis laxa, lesions of, 139-143
- Cyclin, in replicating cells, 30
- Cysts, dermal, formation of, with aging, 85  
proliferation of, ultraviolet-induced, 241, 243
- Cytoheterogeneity, of aging skin, 56-58
- Cytokines, effect of aging on, 151-152
- Daytime functioning, circadian effects on, 343
- Delayed Nonmatching-to-Sample test, for ecological memory assessment, 587
- Dementia(s), cognitive deficits in, measurement of, 519-530  
differential diagnosis of, 614-621  
EEG sleep in, 262-264  
identification of, 614-621  
in Alzheimer's disease, 533-534  
intrusion errors in, 621-627  
judgment and, 491-495  
level of, and independent living skills, 428  
memory disorders in, 572  
mental status examinations in, correlation of, 557-559  
severe, assessment of, 536-540  
sleep apnea and, 353  
sleep deprivation in, 265-266  
sleep stages in, 411  
psychometric correlates of, 384  
with secondary depression, sleep changes in, 264
- Dementia Mood Assessment Scale, 453
- Dementia Rating Scale, for cognitive deficit measurement, 521-522
- DeMorgan's spots, 191
- Denial, in dementia, 482  
with brain lesions, 442
- Depressants, and drug-induced insomnia, 398-399  
and drug-induced sleepiness, 397
- Depression, and memory impairment, 572  
and sleep deprivation, 417  
antihypertensive agents in, 823-824  
differential diagnosis of, EEG sleep in, 262-264  
drug-induced, 445  
in disease states, 444-445  
late-life, 259-273  
EEG sleep in, 260-262  
irreversibility hypothesis of, 270  
maintenance therapy for, 264-267  
recurrence of, prediction of, 267  
treatment of, 268-269  
reduced REM latency in, 417
- sleep changes in, 263, 411  
sleep deprivation in, 265-266  
sleep-disordered breathing in, 267  
with aging, 506-507  
with brain lesions, 442
- Dermal/epidermal junction, of aging skin, 56-57
- Dermatitis, contact, 194-195  
prevalence rates for, 47  
exfoliative, 194  
seborrheic, prevalence rates for, 47  
with declining sebum secretion rate, 113-114
- stasis, 203-204
- Dermatologic disease, population demographics and, 45-49
- Dermatologists, utilization of, 49-50
- Dermatology, geriatric, 1-252
- Dermatophytosis, prevalence rates for, 46
- Dermatosis papulosa nigra, 190
- Dermis, aging, changes in, 133-139  
connective tissue biochemistry of, 127-147  
morphology of, 59-60  
photoaged, repair of, 246-247  
structure of, 133-134
- Desynchronization, spontaneous internal, in free-running conditions, 336-337  
tendency toward, age and, 339-340
- Diabetes mellitus, antihypertensive agents in, 818-820  
skin changes with, electron microscopy of, 84
- Dietary changes, for hypertension, 770, 777  
precautions in, 781-782  
rationale for, 792-794  
in Heartsavers Lifestyle Management Program, 796  
individualized, for hypertension, 783-784
- Dietary history, assessment of, in dietary hypertension therapy, 778-779
- Dietary Intervention Study of Hypertension, 773-775
- Difference scores, on Wechsler Memory Scale-Revised, 617-619
- Diltiazem, cost of, 833  
annual, 837  
for hypertension, 807  
in coronary artery disease, 816
- DISH. See *Dietary Intervention Study of Hypertension*.
- Disinhibition, in dementia, 493
- Distractability, and performance speed, 510
- Diuretics, adverse effects of, 693  
cost of, 832-833  
annual, 837  
for hypertension, 804-806  
effect on concomitant disease, 699  
in congestive heart failure, 817  
in depression, 824

- in diabetes mellitus, 819
- in renal disease, 821
- quality of life with, 710
- DNA synthesis, and cellular senescence, 30
- Down's syndrome, similarities to Alzheimer's disease, 430-431
- Drug(s), and depression, 445
  - and mania, 446
  - and sleep disorders, in aging, 395-404
  - pharmacokinetics of, aging and, 395-397
- Drug reactions, in Hypertension Detection and Follow-up Program, 680-681
- Drug therapy, memory disorders with, 573
- Dry skin, 196-197
  - with declining sebum secretion rate, 113
- Dysdifferentiation theory, of aging, 13-14
- Dysphoria, late-life, 260
  
- Eating, and blood pressure, 720, 722
- Echocardiography, in hypertension, 729
- Eczema, prevalence rates for, 47
- Eczema craquelle', 196-197
- Education, in hypertension therapy, 777
  - level of, and Halstead-Reitan Test Battery performance, 601
- Elastase, effect on skin aging, 85
- Elastic fibers, cutaneous, 69-78
  - abnormalities of, age-related, 73-77
    - causes of, 84
    - lesions from, 139-143
    - actinic damage to, 72-73, 137
    - biochemistry of, 131-133
      - in aging, 137-139
    - degradation of, in aging skin, 86
    - enzymatic digestion of, 77-78
    - formation of, 71-72
    - hyperplasia of, ultraviolet-induced, 244
    - increase in, with photoaging, 237
    - microscopy of, 70-71
- Elastin, accumulation of, in skin, 139-142
  - age-associated alterations in, 63-65, 127-147
  - biosynthesis of, in aging skin, 86
  - increase of, sun-induced, 226
  - structure of, 132
- Elastoderma, lesions of, 139-142
- Elastoidosis, nodular, 230-231
- Elastosis, actinic, 223, 236
  - histopathology of, 134-135
  - experimental, 227-228
  - infrared-induced, 244-245
  - senile, 223
  - ultraviolet-induced, 240, 242, 244-245
- Elderly, cosmetic therapy for, 219-221
  - cutaneous malignant melanoma in, 171-181
  - hypertension in, basic evaluation of, 717-732
- memory in, assessment of, 555-581
- nonmelanoma skin cancers in, 161-170
- psychology of appearance in, 213-222
- sebum secretion rate in, 110
- severely impaired, neuropsychological assessment of, 531-543
- skin problems in, 189-211
- Electrocardiography, in hypertension, 729
- Electroconvulsive therapy, for depression-associated sleep disturbances, 269
- Electroencephalography, for sleep evaluation, 275
  - in rats, 365
- Electron microscopy, of elastic fiber network of skin, 70-71
  - of sun-induced aging, 226
- Embryogenesis, dermal pigment cells during, 93-94
- epidermal melanocytes during, 95-97
- Enalapril, cost of, 833
  - annual, 837
  - in renal disease, 822
  - quality of life with, 711
- Endocrine disorders, and impotence, 309-310
- Environmental factors, in hypertension, 657-662
- Epidermal thymocyte-activating factor (ETAF), age-related changes in, 156-157
- Epidermis, aging, immune function of, 149-160, 152-154
  - morphology of, 53-59
  - normal turnover of, 121-123
- Epinephrine excretion, correlation with systolic hypertension, 667
- Epithelialization, of open wounds, 184
- Erection, capability of, with aging, 303-310
  - nocturnal, 307
  - sleep-related, changes in, 304-305
  - vascular mechanism of, 306
- Erythema, intermittent, 200-201
- European Working Party on High Blood Pressure in Elderly, clinical drug trials in, 694
  - data analysis of, 683
  - description of, 682-685
  - malignant hypertension in, 684
  - mortality rate in, 684
  - participant characteristics of, 682
  - results of, 683-685
  - sample size of, 683
  - treatment cost effectiveness in, 836-838
  - treatment effectiveness in, 830
  - treatment schedule for, 682
- EWPH. See European Working Party on High Blood Pressure in Elderly.
- Exercise, for hypertension, 777, 782
- Exercise training, for hypertension, 794-795

- Exercise training (*Continued*)  
 in Heartsavers Lifestyle Management Program, 796
- Exfoliative dermatitis, 194
- Extensor forearm skin, electron microscopy of, 80-82
- Eye(s), examination of, in hypertension, 727  
 pigment cells of, 103-105
- Facial hair, excessive, 207
- Fatigue, in older adults, in neuropsychological testing, 596
- Fiber intake, assessment of, in dietary hypertension therapy, 779
- Fibroblast(s), effect of growth factors on, 28
- Fibroblast model, of aging, 23-25
- Fibroepithelial polyp, 190-191
- Finger tapping test, for neuropsychological assessment, 514
- First-Last Name Association, for ecological memory assessment, 587
- Floor effects, in cognitive measurement scales, 520-521
- Flurazepam, effect on sleep-related respiratory disturbance, 400
- Food preferences, assessment of, in dietary hypertension therapy, 778
- Forgetting, rates of, measures of, 614-621
- Free radical(s), and differential gene expression, 14-16
- Free radical damage, oxidative, cellular protective mechanisms against, 6-11
- Free radical theory, of biologic aging, 4-6
- Frontal lobe injury, and indifference to disability, 446-447  
 inappropriateness with, 447
- Functional Communication Profile, 470
- Furosemide, cost of, 833  
 in renal disease, 821
- GABA, reduced, in Alzheimer's disease, 437
- Gastrointestinal changes, age-related, and drug absorption, 395
- Gene expression, differential, free radicals and, 14-16
- General Psychological Well-Being Scale, of quality of life, 708
- Genetic control, of cellular senescence, 29-31
- Geriatric Depression Scale, 450, 507
- Geriatric dermatology, 1-252
- Geriatric Mental Status Schedule, in dementia, 535
- Global Deterioration Scale, in dementia, 536
- Glucocorticoids, effect on fibroblasts, 28
- Glucose intolerance, in hypertension, 643, 728  
 with antihypertensive therapy, 695
- Glutathione system, in cellular protection against oxidative free radical damage, 7-8
- Glycine, in collagen polypeptides, 128-129
- Glycosylation, nonenzymatic, in aging, 12-13
- Grafting, skin, and reversal of sun-induced aging, 227
- Graying of hair, 204-205
- Grip strength test, for neuropsychological assessment, 513-514
- Grooved Pegboard, for neuropsychological assessment, 512-513
- Ground substance, of skin, changes with photoaging, 238
- Growth factors, role in aging, 28-29
- GSH peroxidase, in cellular protection against oxidative free radical damage, 9
- GSH reductase, in cellular protection against oxidative free radical damage, 8
- Hair, 97-100  
 changes in, in elderly, 204-207  
 embryogenesis of, 97-99  
 facial, excessive, 207  
 graying of, 204-205  
 loss of, androgenetic, 205-207  
 pigment cells in, in postnatal life, 99-100
- Halstead Impairment Index, effect of age on, 597
- Halstead-Reitan Test Battery, age-related normative data for, 598-600  
 reliability in, 603-604  
 test time in, 602-603  
 use with older adults, 595-610  
 validity in, 604-606
- Hamilton Depression Scale, for mood assessment, 448-449
- Hayflick model, of aging, 23
- HDFP. See *Hypertension and Detection Follow-up Program*.
- Head injury, closed, effects of, 508
- Health practices, assessment of, in dietary hypertension therapy, 778
- Health services, cost of, 44-45  
 utilization of, dermatological implications of, 49-50
- Heart, examination of, in hypertension, 728
- Heart disease, coronary, hypertension and, 647, 651  
 ischemic, mortality in, 648, 650
- Heart failure, congestive, antihypertensive agents in, 817-818  
 blood pressure and, 647

- Heartsavers Lifestyle Management Program, for hypertension, 796-798
- Heliodermatitis, with photoaging, 237-238
- Hemangioma, cherry, 191
- Hemodialysis, in renal disease, 823
- Herpes zoster, 201-202
- High blood pressure. See *Hypertension*.
- Home Visit Assessment, of independent living skills, 473
- Homeostasis, deficiencies of, and hypertension treatment, 691
- Hopkins Brief Symptom Inventory, of depression, 507
- Hormonal factors, in hypertension, 658, 754
- Humoral immunity, B cells and, 150-151
- Huntington's disease, Alzheimer's disease vs, 602
- Wechsler Memory Scale-Revised for, 611-632
- intrusion errors in, 624-627
- Hydralazine, adverse effects of, 693
- cost of, 833
- annual, 837
- for hypertension, 808
- effect on concomitant disease, 700
- Hydrochlorothiazide, cost of, 833
- for hypertension, 805
- in coronary artery disease, 815
- metoprolol vs, 695
- quality of life with, 710-711
- Hydrocortisone, effect on fibroblasts, 29
- Hydroxylsine, in collagen polypeptides, 129-130
- Hydroxyproline, in collagen polypeptides, 129
- Hyperaldosteronism, and hypertension, 754, 757-759
- Hyperglycemia, association with blood pressure, 643, 728
- Hyperkeratoses, seborrheic, 190
- Hyperparathyroidism, and hypertension, 754, 759
- Hyperpigmentation, of aging skin, 56
- Hypersomnolence, sleep-disordered breathing and, 322, 324
- Hypertension, 639-840
- age-related factors in, 658
- ambulatory monitoring of, 733-751
- central nervous system effects of, 705-706
- classifications of, 645
- comorbid problems with, antihypertensive agents for, 813-828
- confirmation of, 718-726
- definition of, 718-719
- diastolic, isolated, risk of, 652
- differential diagnosis of, 726
- drug therapy models for, cost effectiveness of, 835-839
- electrocardiographic abnormalities with, mortality in, 805
- emergency situations in, 719
- epidemiology of, 639-655
- episodic, ambulatory monitoring in, 746
- etiology of, 657-662
- evaluation of, 717-732
- impaired mental abilities with, 388
- mild, treatment of, 677
- mortality from, 648, 649, 651
- nondrug therapy for, 770, 791-802
- blood lipid changes in, 798
- blood pressure changes in, 797
- difficulties of, 798-800
- disadvantages of, 798-800
- rationale for, 792-794
- pathophysiology of, 657-674
- prevalance of, 644-646
- renovascular, screening tests for, 761-762
- risks of, 646-652
- secondary, 753-768
- causes of, 753-755
- diagnostic evaluation of, 756-762
- endocrine causes of, 757-759
- pragmatic strategy for, 765-766
- prevalence of, 754-755
- therapeutic approaches to, 762-765
- sodium restriction in, 769-789
- stepped care of, benefits of, 681
- cost effectiveness of, 836-838
- referred care vs, 677-679
- systolic, isolated, 665-668
- technical considerations in, 721-723
- treatment of, adverse effects of, 691-702
- clinical trials of, 675-690
- effectiveness of, 830-832
- physiologic changes influencing, 691-692
- recommendations in, 769-770
- vascular system pathology with, 662-665
- weight reduction in, 769-789
- with sleep apnea, 322, 350-351
- with snoring, 350
- Hypertension Detection and Follow-up Program, blood pressure goal status in, 679
- clinical drug trials in, 692-694
- description of, 676-681
- design features of, 676-677
- effectiveness of, 830-831
- mortality in, 680-681
- participant characteristics of, 678
- results of, 677-679
- side effects of, 680
- Hyperthyroidism, blood pressure measurement in, 723
- Hypokalemia, in hypertension, 757
- Hypotension, postprandial, ambulatory monitoring in, 746
- Hypoxemia, in apnea, effects of, 387
- Immune function, epidermal, effect of age on, 149-160

- Impotence, aging and, 301-314  
 definition of, 302-303  
 endocrine disorders and, 309-310  
 etiology of, 303  
 evaluation of, 310-311  
 in elderly, prevalence of, 302  
 neurologic changes and, 308-309  
 pharmacologic causes of, 309  
 psychologic disorders and, 310  
 treatment of, 310-311  
 vascular changes and, 305-308
- Impulsivity, in dementia, 493
- Inappropriateness, with central nervous system dysfunction, 447
- Independent living skills, assessment of, 461-475  
 approaches to, 462-463  
 instruments for, 465-473  
 issues in, 461-465  
 mental status evaluations and, 463-464  
 purposes of, 463  
 definition of, 461  
 insight assessment and, 485
- Index scores, on Wechsler Memory Scale-Revised, 616-617
- Indifference, to physical disability, with neurologic disease, 446-447
- Inflammatory response, age-related decline in, 118-119
- Infrared radiation, and photoaging, 243-246
- Insight, assessment of, methods of, 486-488  
 complexity of, 487  
 definition of, 480  
 mental status assessment of, 477-496  
 theoretical conceptions of, 480-488
- Insomnia, drug-induced, and aging, 398-399  
 sleep-disordered breathing and, 323  
 sleep stages in, 411  
 subjective reports of, 347  
 with late-life depression, treatment of, 268-269
- Instrumental Activities of Daily Living Scale, for independent living skills assessment, 462, 468-469
- Integumental reactivity, age-related decline in, 118-119
- Intelligence, correlation with sleep measures, 352  
 crystallized vs fluid, 536-537, 597  
 role in memory, 568
- Interleukins, effect of aging on, 151-152
- Interpersonal Support Evaluation List, of quality of life, 707
- INTERSALT study, 660
- Intertrigo, 198-199
- Intrusion errors, analysis of, 625  
 as marker of dementia, 621-627  
 on Wechsler Memory Scale-Revised, 617-619
- Itching, 195-196
- Ito, nevus of, 94-95
- Judgment, and dementia, 491-495  
 definition of, 488-489  
 mental status assessment of, 477-496
- Katz Index of ADL, for independent living skills assessment, 467
- Kenny Self-Care Evaluation, for independent living skills assessment, 467
- Keratinization, of aging skin, 57-58
- Keratinocytes, cellular senescence of, 26  
 effect of growth factors on, 28
- Keratoacanthoma, 167-168
- Keratoses, actinic, 163-166, 229-230  
 seborrheic, 189-191
- Kidney. See also under *Renal; Renovascular*  
 function of, decreased, drug elimination with, 396  
 revascularization of, for renovascular hypertension, 764
- Korsakoff's syndrome, amnesia in, 569-570
- Labetolol, cost of, 833  
 for hypertension, 808  
 in renal disease, 821
- Laboratory studies, in hypertension, 728-730
- Lacunae, dermal, formation of, with aging, 85
- Langerhans cells, in immune response, effect of aging on, 153  
 reduced density of, age-related, 155-156
- Language impairment, in Alzheimer's disease, 534
- Late life, sleep and depression in, 259-273
- Laterality, neuropsychological assessment of, 510-511
- Learning, types of, 566-568
- Left ventricular hypertrophy, 729  
 antihypertensive agents in, 816-817
- Left ventricular mass index, correlation with blood pressure, 744
- Leg movements, in sleep loss recovery, 412  
 periodic, in sleep, 356-357  
 effect of drugs on, 401-402
- Lentigo maligna melanoma, 174-175
- Letter Cancellation test, for neuropsychological assessment, 513
- Lichen simplex chronicus, 197-198
- Life span, metabolic expenditure and, 2
- Light exposure, effect on fibroblasts, 29
- Light microscopy, of elastic fiber network of skin, 70-71

- of sun-induced aging, 225-226
- Lipid peroxidation, and aging process, 5
- Lipoproteins, measurement of, in hypertension, 728-729
- Lisinopril, cost of, 833
  - annual, 837
  - in renal disease, 822
- Liver, changes in, drug elimination with, 396
- Locomotion, generators of, 502
- Lubben Social Network Scale, of quality of life, 707
- Lymph nodes, dissection of, for malignant melanoma, 179
- Lymphoid tissue, skin-associated, 153
- Lymphokines, in aging, 151-158
  
- Magnesium, in hypertension, 661-662
- Maillard reaction, in aging, 12
- Malignant melanoma, clinical classification of, 173-175
  - clinicopathologic types of, 171
  - cutaneous, in older patient, 171-181
  - invasive, age-specific incidence of, 172
  - management of, 179-180
  - pathology of, 175-179
  - prognosis of, 175-179
- Mania, drug-induced, 446
  - with focal brain injury, 445-446
- Manometers, blood pressure, accuracy of, 721-722
- Material specificity, in memory assessment, 577-578
- Mattis Dementia Rating Scale, in dementia assessment, 535-536, 539, 553
- Meal patterns, assessment of, in dietary hypertension therapy, 778
- Medical history, in hypertension, 726-728
- Medical illness, and depression, 445
- Medications, and impotence, 309
- Melanin(s), biologic value of, 105-106
  - production of, in nevi, 100
- Melanocytes. See also *Pigment cells*.
  - biologic value of, 105-106
  - dermal, in postnatal life, 94-95
  - effect of growth factors on, 28
  - epidermal, during embryogenesis, 95-97
  - lives of, 91-108
  - origin of, 91-93
- Melanoma, malignant. See *Malignant melanoma*.
- Memory, anterograde vs retrograde, 566
  - assessment of, 565-581. See also *Memory assessment*.
  - clinical disorders of, 568-573. See also *Memory impairment*.
  - definition of, 565
  - difficulties with, snoring and, 386
- general vs delayed, on Wechsler Memory Scale-Revised, 616-619
- in affect assessment, 442
- interactions with sleep, in animals, 371-375
- in older subjects, 414
- psychometric tests for, characteristics of, 573-578
- short-term vs long-term, 567
- types of, 566-568
- visual, measures of, in dementia assessment, 614-621
- Memory assessment, ecological, 583-594
  - findings in, 591-593
  - method of, 585-586
  - results in, 586-591
  - subjects in, 585-586
  - test battery for, 587
- material specificity in, 577-578
- on Wechsler Memory Scale-Revised, 616
- Memory impairment, age-associated, definition of, 584
  - assessment of, 576-577
  - denial of, in dementia, 480
  - diagnosis of, 576
  - global vs specific, 569
  - in Alzheimer's disease, 533
  - psychogenic, 572
- Mental function, areas for testing, 547
  - sleep disturbances and, 384
- Mental status assessment, 545-564
  - approaches to, 478-479
  - brief examination for, 548-552
  - in independent living skills assessment, 463-464
- Mental Status Questionnaire, in dementia, 535
- Mental tracking, decreased, in dementia, 492
- Metabolic alkalosis, in hypertension, 757
- Metabolic expenditure, and life span, 2
- Metamemory, assessment of, 481
- Metanephrenes, in hypertension, 667, 757
- Methyldopa, cost of, 833
  - annual, 837
  - for hypertension, 809
    - effect on concomitant disease, 700
    - quality of life with, 710-711
- Methylxanthines, and drug-induced insomnia, 398-399
- Metoprolol, cost of, 833
  - for hypertension, 806-807
  - hydrochlorothiazide vs, 695
  - quality of life with, 706, 710
  - side effects of, 696
- Mice, age-related sleep changes in, 365-366
- Microvasculature, changes in, age-related, 78-84
  - microscopy of, 80-84
  - of skin, changes in, physiologic, 117-118
    - with photoaging, 237

- Milia, colloid, 230-231
- Mini-Mental Status Examination, administration of, 549-550
- correlation with Alzheimer's Disease Assessment Scale, 556
- for cognitive deficit measurement, 522
- in dementia, 492, 535
- of quality of life, 708
- Minnesota Multiphasic Personality Inventory, for personality assessment, 450-451
- Minoxidil, adverse effects of, 693
- cost of, 833
- effect on concomitant disease, 700
- Misplaced Objects Test, for ecological memory assessment, 587
- Mongolian blue spot, 95
- Monoamine oxidase inhibitors, for depression-associated sleep disturbances, 269
- Monoclonal gammopathies, age-related, 150
- Mood, assessment of, 441-459
- recent developments in, 452-454
  - strategies for, 448-450
  - changes in, in disease states, 444-448
- Motor activity, feedback component of, 503
- goal-driven, 502
  - hierarchical organization of, 500-503
- Motor testing, effect of depression on, 506-507
- Multi-Score Depression Inventory, 507
- Myocardial infarction, antihypertensive agents in, 814-815
- Myoclonus, nocturnal, with sleep apnea, 356-357
- Nadolol, cost of, 833
- in renal disease, 821
- Nail changes, in elderly, 207-208
- Name-Face Association Test, for ecological memory assessment, 587, 589
- Napping, increase with age, 278
- Narcolepsy, performance deficits in, 387
- National High Blood Pressure Education Program, 675
- Nervous system, sympathetic, role in hypertension, 663, 666-668
- Neural crest, formation of, 92-93
- pigment cell origin in, 91-93
- Neurobehavioral Cognitive Status Examination, for patient classification, 548
- of cognitive function, 554
- Neurodegenerative diseases, similarities to Alzheimer's disease, 430
- Neurofibrillary tangles, in Alzheimer's disease, 429
- association with cognitive deficits, 431-433
- Neurologic disorders, age-related, 507-509
- and impotence, 308-309
- Neuropsychologic evaluation, new developments in, 425-632
- Neuropsychologic function, and sleep, 381-394
- assessment of, age effects on, 596-601
  - recent developments in, 452-456
  - impairment of, sleep apnea and, 353-354
- Neuropsychology, role in Alzheimer's disease, 425-428
- Neuropsychology Behavior and Affect Profile, for personality assessment, 454-455
- Neurotransmitters, in Alzheimer's disease, 434-438
- Nevus(i), 100-103
- acquired, 101-103
  - blue, 94
  - congenital, 101-102
- Nifedipine, cost of, 833
- annual, 837
  - for hypertension, 807
  - in coronary artery disease, 816
  - in renal disease, 822-823
- Nodular elastoidosis, 230-231
- Nodular melanoma, 173
- Nonenzymatic glycosylation, in aging, 12-13
- Nonfibroblast lines, senescence in, 25-26
- Nonmelanoma skin cancers, in elderly, 161-170
- Nonverbal memory items, for cognitive measurement scales, 526-527
- Norepinephrine, circulating levels of, in hypertension, 661, 663, 666
- Normative tables, for test evaluation, problems with, 574
- Nortriptyline, for late-life depression, findings in, 264
- Nursing home patients, sleep problems in, 354-355
- Nutrition counseling, individualized, for hypertension therapy, 776, 783-784
- Obesity, and hypertension, 658-659, 771
- Obsession-compulsion, and performance speed, 510
- Older adult, assessment of, special needs in, 595-596
- hypertension in, evaluation of, 717-732
  - mood assessment in, 442-443
  - neuropsychological assessment of, 509-514
  - psychomotor assessment of, 499-515
  - use of Halstead-Reitan Test Battery with, 595-610
- Older American Research and Service Center scale, for independent living skills assessment, 469

- Oral cavity, nevi in, 103-104  
 Oral hygiene, assessment of, in dietary hypertension therapy, 778  
 Ota, nevus of, 94-95  
 Outlook, effect of appearance on, 220  
 Overweight, and hypertension, 658-659, 771  
 Oxprenolol, quality of life with, 711  
 Oxygen, concentrations of, effect on fibroblasts, 29  
     consumption of, in wound healing, 186  
 Oxygen radicals, in cutaneous malignancy, 106
- Pain, perception of, age-related decline in, 119-120  
 Parkinson's disease, depression in, 444-445  
 Pemphigoid, bullous, 193  
 Penile tumescence, nocturnal, normal, 303-304  
 Perceptual discrimination, impaired, in Alzheimer's disease, 534  
 Performance Activities of Daily Living Scale, for independent living skills assessment, 469-470  
 Performance efficiency, tests of, correlations with REM sleep, 382  
     with sleep loss, 405, 413-416  
 Periodic breathing, in sleep apnea, 317  
 Peripheral vascular system, in hypertension, 658, 663  
 Personality, assessment of, 441-459  
     recent developments in, 454-456  
     strategies for, 450-452  
     changes in, with central nervous system dysfunction, 446-448  
     effect of normal aging on, 443  
 Pheochromocytoma, and hypertension, 754, 757  
 Photoaging, 235-251  
     action spectrum of, experimental studies in, 239-246  
     aging vs. histologic comparisons of, 235-239  
     prevention of, 246-247  
     solar-simulating radiation and, 242-243  
     therapy for, 247-249  
     ultraviolet and, 239-243  
 Physical activity, assessment of, in dietary hypertension therapy, 778  
 Physical examination, in hypertension, 726-728  
 Physical Self-Maintenance Scale, for independent living skills assessment, 468-469  
 Physical status, effect on neuropsychological testing, 442, 596  
 Pigment cells. See also *Melanocytes*.  
     dermal, 93-97  
         during embryogenesis, 93-94  
         epidermal, postnatal, 96-98  
         in hair, in postnatal life, 99-100  
         lives of, 91-108  
 Pigmentation, irregular, with sun exposure, 229  
 Planning items, for cognitive measurement scales, 526-527  
 Plasma renin activity, in renovascular hypertension, 665-666, 761-762  
 Polyp, fibroepithelial, 190-191  
 Population, aging of, dermatologic implications of, 41-51  
 Posture, and blood pressure, 720, 722  
 Potassium, for hypertension, 770  
     in hypertension, 661-662, 728  
 Potassium chloride, cost of, annual, 837  
 Pragnosia, following brain injury, 448  
 Prazosin, cost of, 833  
     for hypertension, 808  
     in renal disease, 822  
 Premature aging, of skin, 235-251  
 Procollagen, synthesis of, 130  
 Proline, in collagen polypeptides, 129  
 Prolyl hydroxylase, catalytic activity of, in aging skin, 136  
 Propranolol, blood lipid changes in, 798  
     cost of, 833  
     following myocardial infarction, 814-815  
     for hypertension, 806-807  
     quality of life with, 710-711  
 Protein oxidation, and aging process, 5  
 Proverb interpretation, for judgment assessment, 489  
 Prurigo nodularis, 197-198  
 Pruritus, 195-196  
 Pseudodementia, depressive, sleep changes in, 264  
 Pseudohypertension, 645  
     identification of, 725  
 PSMSADL scales, for independent living skills assessment, 468-469  
 Psychoeducational therapy, for depression-associated sleep disturbances, 269  
 Psychologic disorders, and impotence, 310  
 Psychometrics, relationships to EEG-defined sleep stages, 381-384  
 Psychomotor performance, age-related behavioral slowing of, 504-506  
     age-related neuropsychological changes in, 504-509  
     assessment of, 499-515  
     neuroanatomical correlates of, 503-504  
     with sleep loss, 405  
 Psychotherapy, for depression-associated sleep disturbances, 268

- Pulmonary disease, chronic obstructive, antihypertensive agents in, 818
- PULSES Profile, for independent living skills assessment, 466
- Purdue Pegboard, for neuropsychological assessment, 512
- Purpose, in psychomotor activity, 501
- Purpura, senile, 202
- Quality of life, antihypertensive therapy and, 696-697, 703-715  
as outcome of therapy, 704, 705  
definition of, 703-706  
domains of, 707  
measures of, 704, 706-709
- Race, association with blood pressure, 643-644
- Racemization, amino acid, in aging, 11-12
- Radiation, and photoaging, 242-246
- Rate-of-living theory, of biologic aging, 2-4
- Rats, circadian sleep-wake rhythm in, 364-365
- Raven Progressive Matrices, for judgment assessment, 489
- Reaction time, in ecological memory assessment, 587  
slowing of, in neurologic disease, 508  
with aging, 504  
with sleep loss, 414-415
- Reasoning, investigation of, in dementia, 495
- Reciprocal tapping test, for neuropsychological assessment, 514
- Relaxation training, for hypertension, 795
- Reliability, in cognitive deficit measurement, 523-524  
in Halstead-Reitan Test Battery, 603-604
- REM sleep, 409-412  
and penile erections, 303  
in depression, 260-261  
in older subjects, 281  
interaction with slow-wave sleep, 417  
latency of, in sleep loss recovery, 411, 413
- Renal arteriography, in renovascular hypertension, 762
- Renal disease, and hypertension, 651, 658, 754, 759-760, 763  
antihypertensive agents in, 820-823
- Renin, role in hypertension, 665-666, 761-762
- Renovascular hypertension, 760-761  
therapy for, 763-765
- Reserpine, cost of, 833  
annual, 837  
for hypertension, 808-809
- Respiratory disturbance, index of, 350  
sleep-related, effect of drugs on, 400-401  
neuropsychologic impairment in, 389  
psychometric correlates of, 384-388
- Rete pegs, retraction of, in aging skin, 55
- Retinal epithelium, pigment cells of, 103-105
- Retinoic acid, for photoaged skin, 247-249
- Rhinophyma, 200-201
- Rotary Pursuit, for neuropsychological assessment, 513
- Rough endoplasmic reticulum, electron microscopy of, 82
- S-Transferases, in cellular protection against oxidative free radical damage, 9
- Sacral spot, 95
- Salt consumption, and hypertension, 659-661, 728, 771-772, 779
- Savings scores, on Wechsler Memory Scale-Revised, 619-621
- Scales of Independent Behavior, for independent living skills assessment, 471
- Schiff base, formation of, in aging, 12
- Sebaceous gland, changes in, 109-114  
hyperplasia of, 192
- Seborrheic dermatitis, prevalence rates for, 47  
with declining sebum secretion rate, 113-114
- Seborrheic keratoses, 189-191
- Sebum secretion, changes in, 109-114  
rate of, decline with age, 112-114  
measurement of, 109-110  
variability of, 110-113  
ultimate levels of, 113
- Selective Reminding Test, for ecological memory assessment, 587, 589-590
- Self-examination, for malignant melanoma, 179
- Self-maintenance activities, assessment of, 462
- Self-perception, appearance and, 215-217  
cosmetic use and, 219-220
- Senile plaques, in Alzheimer's disease, 429  
association with cognitive deficits, 431-433
- Sensory deficits, in neuropsychological testing, 596  
with aging, 505
- Severe Impairment Battery, for severe dementia, 538
- SHEP. See *Systolic Hypertension in the Elderly Program*.
- Shift work, intolerance to, 343
- Shingles, 201-202
- Shipley Institute of Living Scale, for judgment assessment, 489

- Short Portable Mental Status Questionnaire, administration of, 550-552  
in dementia, 535
- Sickness Impact Profile, of quality of life, 708
- Similarities subtest, for judgment assessment, 490
- Skills, assessment of, in dietary hypertension therapy, 778
- Skin, aged, abnormalities in, 69-90, 139-143  
light microscopic appearance of, 54  
morphology of, 53-67  
physiologic changes in, 115-125  
atrophy of, with sun exposure, 230, 237  
barrier properties of, 115-117  
cancers of, nonmelanoma, in elderly, 161-170  
dermal/epidermal surface of, electron microscopic appearance of, 55  
geometric patterns of, 54  
grafting of, and reversal of sun-induced aging, 227  
immune function of, age-related alteration in, 152-158  
microvasculature of, changes in, physiologic, 117-118  
with photoaging, 237  
normal, connective tissue biochemistry of, 128-133  
percutaneous adsorption by, 116-117  
pigment cells of, 93-97  
problems of, common, in elderly, 189-211  
prevalence rates for, 46-48  
tags of, 190-191  
tumors of, benign, 189-192  
prevalence rates for, 46  
vulnerability of, with aging, 119-120
- Sleep, amount of, extremes of, 278  
methods of determining, 277  
and aging, in animals, 363-379  
changes in, age-related, 275-287  
in animals, 363-369  
thermoregulation in, 368  
interpretation of, 283-284  
cicadian rhythm in, in animals, 369-370  
complaints about, subjective reports of, 347-348  
continuity of, 279  
and memory, in animals, 371  
in rats, 364-365  
cycles of, in depression, 260  
deprivation of. See *Sleep deprivation*.  
dimensions of, 275-276  
disorders of, disturbances vs, 285  
drugs and, 395-404  
epidemiology of, 347-362  
implications of, 284-286
- disruption of, as sleep deprivation, 416-417  
disturbances of, and mental function, 285, 384  
duration of, in rats, 364  
total, 407-408
- EEG, in late-life depression, 260-262
- fragmentation of, in sleep apnea, 322
- in Alzheimer's disease, 289-299
- in late life, 259-273
- in nursing homes, 354-355
- interactions with cognitive function, in animals, 371-375
- leg movements in, 356-357, 401-402, 412
- loss of. See *Sleep loss*.
- neuropsychologic function and, 381-394
- nocturnal, characteristics of, 283
- onset latency of, 279, 408-410  
test of, 348
- paradoxical, and performance, in animals, 372-374
- patterns of, 276-280
- physiologic function and, in animals, 368-369
- REM. See *REM sleep*.
- slow-wave, interaction with REM sleep, 417
- stages of, 280-281, 407-413  
baseline and recovery, 407  
EEG-defined, 381-384  
psychometric correlates of, 382
- structure of, 280-281
- subjective evaluations of, 281-283
- timing of, 278
- transient arousal from, 409
- Sleep apnea, 350-353  
and neuropsychological impairment, 353-354
- arrhythmias with, 322
- clinical features of, 321-322
- cognitive impairment with, 354
- definition of, 315
- frequency of, 317-318
- in elderly, 315-329  
prevalence of, 351-353  
mortality in, 323, 355-356
- pathogenesis of, 317-320
- polygraphic tracings of, 316
- prevalence of, 316-317, 351-353
- psychometric correlates of, 385
- syndrome of, in late-life depression, 267
- therapy for, 324-325
- types of, 350
- with dementia, 353
- Sleep deprivation, in dementia, 265-266  
in depression, 265-266, 417  
REM sleep response to, 262
- sleep disruption as, 416-417
- Sleep diary, correlation with self estimates, 276

- Sleep-disordered breathing, clinical evaluation of, 323-324  
in depression, 267
- Sleep disorders, in elderly, 259-420
- Sleep log, correlation with self estimates, 276
- Sleep loss, and sleep onset latency, 408-410  
in aging, 405-420  
implications of, 417-418  
performance in, 413-416  
recovery from, 407-413  
studies of, 406
- Sleep/wake patterns, circadian, in rats, 365  
fragmentation with aging, 367  
in Alzheimer's disease, 289-299
- Sleepiness, daytime, drug-induced, 402  
excessive, 348-349  
drug-induced, and aging, 397-398  
sleep loss and, 406
- Slow-wave sleep, interaction with REM sleep, 417
- Smoking, and blood pressure, 722  
and impotence, 305
- Snoring, and memory difficulties, 386  
in sleep apnea, 321  
prevalence of, 349-350  
with airway obstruction, 349
- Social support, assessment of, in dietary hypertension therapy, 778
- Socializing, effect of appearance on, 220
- Sodium, and hypertension, 659-661, 728, 771-772, 779
- Sodium restriction, for hypertension, 770  
benefits of, 780-781  
efficacy of, 772-775  
essential elements of, 776-777  
failure prevention in, 783  
guidelines for, 775-780  
precautions in, 780-782
- Sodium sensitivity, in elderly, 660
- Solar elastosis, 223
- Solar-simulating radiation, and photoaging, 242-243
- Somatostatin, decreased, in Alzheimer's disease, 437
- Speed, performance, neuropsychological assessment of, 509-510
- Sphygmomanometers, dimensions of, 721
- Sphygmomanometry, ambulatory blood pressure monitoring vs, 739-741
- Spider veins, 203
- Squamous cell carcinoma, invasive, progression of actinic keratoses to, 162-166
- SRIF, correlation with dementia severity, in Alzheimer's disease, 437
- Standardization, in testing, definition of, 477-478
- Statin, in nonreplicating cells, 30
- Stimulants, and drug-induced insomnia, 398-399
- and drug-induced sleepiness, 397
- Stomatitis, angular, 199-200
- Stratum corneum, barrier properties of, 115  
normal turnover of, 121-123
- Stress management training, for hypertension, 795
- in Heartsavers Lifestyle Management Program, 796
- Stroke, antihypertensive agents in, 823  
depression in, 445  
hypertension and, 651  
with snoring, 350
- Structured Activities of Independent Living Scale (SAILS), for Alzheimer's disease, 428, 472
- Sun, aging of skin by, 223-233  
exposure to, and skin cancer, 162  
effect on fibroblasts, 29
- Sunscreen, prevention of photoaging with, 246-247
- Superficial spreading melanoma, 173
- Superoxide dismutase, in cellular protection against oxidative free radical damage, 6
- Symbol digit modalities, neuropsychological assessment of, 511
- Systolic Hypertension in the Elderly Program, 676  
quality of life measurements in, 712
- Tactual Performance Test, age-related decrements in, 599-600
- Telangiectasia, with sun exposure, 229-230
- Telephone Test, for ecological memory assessment, 587
- Temperature, ambient, effect on blood pressure, 645  
free-running rhythm of, 338-339  
oral, 332  
rectal, 335  
regulation of, and age-related sleep changes, in animals, 368
- Temporal lobe lesions, and amnesia, 571
- Terazosin, cost of, 833
- Test construction, principles of, in mental status examinations, 546
- Testing time, in Halstead-Reitan Test Battery, 602-603
- Thematic Apperception Test, for insight assessment, 486
- Theophylline, and drug-induced insomnia, 398-399
- Thermoregulation, and age-related sleep changes, in animals, 368
- Thiazides, adverse effects of, 693  
effect on concomitant disease, 699  
in coronary artery disease, 815  
quality of life with, 710

- Thymus, relationship to skin, in immune response, 153
- Time cues, and circadian rhythm entrainment, 342
- Timolol, following myocardial infarction, 814-815
- Tocopherol, in cellular protection against oxidative free radical damage, 9
- Topographic Memory Test, for ecological memory assessment, 587
- Trailmaking Test, age-related decrements in, 599  
for neuropsychological assessment, 511-512
- Triamterene, cost of, annual, 837
- Triazolam, effect on sleep-related respiratory disturbance, 400
- Tricyclic antidepressants, and periodic leg movements in sleep, 401  
for depression-associated sleep disturbances, 268  
for sleep apnea, 325
- Trimazosin, in renal disease, 822
- Ulcers, stasis, 203-204
- Ultraviolet, and photoaging, 239-243  
effect on epidermal immune function, 154  
wavelengths affecting skin, 231-232
- Upper airway, obstruction of, and sleep apnea, 317, 319-320  
clinical significance of, 322-323
- Urate, in cellular protection against oxidative free radical damage, 10
- Uric acid, in hypertension, 728  
with antihypertensive therapy, 694
- Urinalysis, in hypertension, 728
- Uvulopelatopharyngoplasty, for sleep apnea, 325
- Validity, criterion-related, in mental status examinations, 547  
in Halstead-Reitan Test Battery, 604-606
- Vanillylmandelic acid, urinary, in hypertension, 757
- Vascular changes, and impotence, 305-308  
functional, and hypertension, 663-665  
structural, with aging, 662-663  
isolated systolic hypertension in, 665-666
- Vascular disorders, depression in, 444  
in elderly, 202-204
- Vasoconstriction, in hypertension, 664
- Vasodilators, adverse effects of, 693  
cost of, 833  
for hypertension, 808  
effect on concomitant disease, 700  
quality of life with, 710
- Veil cells, in aging skin, 87
- Venous lakes, 202
- Ventilatory drive, abnormalities of, and sleep apnea, 318
- Venule, postcapillary, in aging skin, 87-88  
thickening of, 80  
thinning of, 83
- Verapamil, cost of, 833  
annual, 837  
for hypertension, 807  
in coronary artery disease, 816  
in renal disease, 822-823
- Verbal memory items, for cognitive measurement scales, 525-526  
on Wechsler Memory Scale-Revised, 616
- Verbal reasoning items, for cognitive measurement scales, 525
- Visual Analogue Mood Scales, for mood assessment, 453-454
- Visual memory, assessment of, in dementia assessment, 614-621
- Visual Reproduction Test, of Wechsler Memory Scale-Revised, intrusion errors on, 622-624
- Visual-spatial reasoning items, for cognitive measurement scales, 526
- Vocabulary items, for cognitive measurement scales, 524-525
- Water loss, transepidermal, 116
- Wechsler Adult Intelligence Scale-Revised, elderly sample sizes in, 574
- Wechsler Memory Scale-Revised, attention vs memory on, 613  
characteristics of, 575  
comparison with original scale, 612-613  
difference scores on, 617-619  
floor effects of, 628  
for differentiating dementias, 611-632  
immediate vs delayed memory on, 613  
index scores on, 613, 616-617  
intrusion errors on, as marker of dementia, 621-627  
normative data for, limitations in, 629  
savings scores on, 619-621  
subject groups of, 616-617  
verbal bias of, 628
- Weight reduction, for hypertension, 770  
benefits of, 780-781  
efficacy of, 772-775  
essential elements of, 776-777  
failure prevention in, 783  
guidelines for, 775-780  
precautions in, 780, 782-783  
for sleep apnea, 325
- in Heartsavers Lifestyle Management Program, 796

- Well-being, appearance and, in elderly, 214-218
- Wernicke-Korsakoff syndrome, amnesia in, 570
- Wisconsin Card Sorting Test, for judgment assessment, 489
- Wound healing, aging and, 120-121, 183-189
- biosynthetic activity in, 186-187
- cellular activities in, 185-186
- clinical observations in, 183-185
- Wrinkles, in elderly, 208-209
- Zung depression scale, for mood assessment, 449, 507

